Global Gastroparesis Drugs Market Size study, by Drug Class (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injections), Disease Type, End-use and Regional Forecasts 2022-2032

Description

Global Gastroparesis Drugs Market is valued approximately at USD 4.6 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.60% over the forecast period 2024-2032. Gastroparesis, characterized by delayed gastric emptying without mechanical obstruction, poses a multifaceted treatment challenge due to its complex etiology. The growing prevalence of diabetes mellitus, particularly Type 1 and Type 2, is a key contributor to rising gastroparesis diagnoses globally. As a result, demand for pharmacological interventions has surged, paving the way for a competitive and innovation-driven gastroparesis drugs market. Emerging therapeutics are targeting not just symptomatic relief, but also the underlying pathophysiology, offering healthcare providers more options for tailoring treatments to patient profiles.

The market has seen considerable traction around prokinetic agents, which enhance gastric motility and offer foundational management for gastroparesis. However, as treatment-resistant cases rise, attention has shifted toward newer formulations of antiemetics and botulinum toxin injections, which offer relief for nausea, vomiting, and abdominal discomfort. Pharmaceutical companies are reconfiguring existing drug molecules for enhanced gastrointestinal selectivity, while also exploring novel mechanisms of action to mitigate side effects and improve patient adherence. Regulatory bodies such as the FDA and EMA have been expediting approvals for orphan-designated drugs in gastroparesis, further spurring clinical trial investments.

Despite this momentum, the market faces certain friction points. The variable efficacy of existing therapies, high cost of advanced treatments, and the absence of curative options are significant concerns. Moreover, gastroparesis often presents as a secondary condition, making early diagnosis elusive and complicating therapeutic response tracking. Nevertheless, the integration of digital symptom tracking tools, real-world evidence-based data, and gastroenterology-focused telemedicine consultations is expected to refine clinical pathways and foster earlier intervention, indirectly propelling drug demand.

Pharmaceutical companies are actively forming partnerships with academic institutions and biotechnology startups to co-develop promising drug candidates. Meanwhile, distribution strategies are evolving with increased penetration through hospital pharmacies and specialty clinics. As awareness of functional gastrointestinal disorders grows, so too does the influence of patient advocacy groups, who are demanding better access, insurance coverage, and treatment transparency. This shift is encouraging pharma firms to enhance patient-centric strategies and expand post-launch support programs, especially in chronic cases requiring long-term care.

Regionally, North America commands the largest share of the gastroparesis drugs market due to robust healthcare reimbursement systems, high diabetes prevalence, and a well-established network of gastroenterologists. Europe follows closely, particularly driven by countries like Germany, France, and the UK, where clinical research in motility disorders is well funded. Asia Pacific is expected to register the highest CAGR over the forecast period, catalyzed by improving diagnostic infrastructure, increasing patient pool, and expanding pharmaceutical sales networks in countries like India, China, and Japan. Meanwhile, Latin America and the Middle East & Africa present untapped potential as global manufacturers turn their focus to broader market penetration and localization strategies.

Major market player included in this report are:

Pfizer Inc.
Takeda Pharmaceutical Company Limited
Abbott Laboratories
Teva Pharmaceutical Industries Ltd.
Evoke Pharma, Inc.
Salix Pharmaceuticals, Ltd.
Medtronic plc
Johnson & Johnson Services, Inc.
Mylan N.V.
Theravance Biopharma
AstraZeneca plc
Cadila Healthcare Limited (Zydus)
ANI Pharmaceuticals, Inc.
Cipla Ltd.
Neurogastrx, Inc.

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Prokinetic Agents
Antiemetic Agents
Botulinum Toxin Injections

By Disease Type

Diabetic Gastroparesis
Idiopathic Gastroparesis
Post-surgical Gastroparesis
Others

By End-use

Hospitals
Clinics
Homecare
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year: 2022
Base year: 2023
Forecast period: 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Gastroparesis Drugs Market Executive Summary

1.1. Global Gastroparesis Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Drug Class (Prokinetic Agents; Antiemetic Agents; Botulinum Toxin Injections)
- 1.3.2. By Disease Type (Diabetic Gastroparesis; Idiopathic Gastroparesis; Post-surgical Gastroparesis; Others)
- 1.3.3. By End-use (Hospitals; Clinics; Homecare; Others)
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Gastroparesis Drugs Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Provider Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Patient Awareness & Adoption
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Gastroparesis Drugs Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising diabetes prevalence driving gastroparesis incidence
- 3.1.2. Expansion of prokinetic and antiemetic therapeutic pipelines
- 3.1.3. Increasing regulatory approvals for novel orphan drugs
3.2. Market Challenges
- 3.2.1. Variable efficacy and side-effect profiles of existing therapies
- 3.2.2. High treatment costs and reimbursement hurdles
- 3.2.3. Difficulties in early diagnosis and disease monitoring
3.3. Market Opportunities
- 3.3.1. Digital health integrations and real-world evidence collection
- 3.3.2. Clinical collaborations for next-gen drug candidates
- 3.3.3. Expansion into emerging markets with growing healthcare access

Chapter 4. Global Gastroparesis Drugs Market Industry Analysis

4.1. Porter's Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Gastroparesis Drugs Market Size & Forecasts by Drug Class, 2022-2032

5.1. Segment Dashboard
5.2. Prokinetic Agents Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.3. Antiemetic Agents Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.4. Botulinum Toxin Injections Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 6. Global Gastroparesis Drugs Market Size & Forecasts by Disease Type, 2022-2032

6.1. Segment Dashboard
6.2. Diabetic Gastroparesis Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.3. Idiopathic Gastroparesis Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.4. Post-surgical Gastroparesis Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.5. Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 7. Global Gastroparesis Drugs Market Size & Forecasts by End-use, 2022-2032

7.1. Segment Dashboard
7.2. Hospitals Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.3. Clinics Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.4. Homecare Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.5. Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 8. Global Gastroparesis Drugs Market Size & Forecasts by Region, 2022-2032

8.1. North America Market
- 8.1.1. U.S. Gastroparesis Drugs Market
- 8.1.2. Canada Gastroparesis Drugs Market
8.2. Europe Market
- 8.2.1. UK Gastroparesis Drugs Market
- 8.2.2. Germany Gastroparesis Drugs Market
- 8.2.3. France Gastroparesis Drugs Market
- 8.2.4. Spain Gastroparesis Drugs Market
- 8.2.5. Italy Gastroparesis Drugs Market
- 8.2.6. Rest of Europe Gastroparesis Drugs Market
8.3. Asia Pacific Market
- 8.3.1. China Gastroparesis Drugs Market
- 8.3.2. India Gastroparesis Drugs Market
- 8.3.3. Japan Gastroparesis Drugs Market
- 8.3.4. Australia Gastroparesis Drugs Market
- 8.3.5. South Korea Gastroparesis Drugs Market
- 8.3.6. Rest of Asia Pacific Gastroparesis Drugs Market
8.4. Latin America Market
- 8.4.1. Brazil Gastroparesis Drugs Market
- 8.4.2. Mexico Gastroparesis Drugs Market
- 8.4.3. Rest of Latin America Gastroparesis Drugs Market
8.5. Middle East & Africa Market
- 8.5.1. Saudi Arabia Gastroparesis Drugs Market
- 8.5.2. South Africa Gastroparesis Drugs Market
- 8.5.3. Rest of Middle East & Africa Gastroparesis Drugs Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1. Pfizer Inc.
- 9.1.2. Takeda Pharmaceutical Company Limited
- 9.1.3. Abbott Laboratories
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Pfizer Inc.
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Teva Pharmaceutical Industries Ltd.
- 9.3.3. Evoke Pharma, Inc.
- 9.3.4. Medtronic plc
- 9.3.5. Johnson & Johnson Services, Inc.
- 9.3.6. Salix Pharmaceuticals, Ltd.
- 9.3.7. Mylan N.V.
- 9.3.8. Theravance Biopharma
- 9.3.9. AstraZeneca plc
- 9.3.10. Cadila Healthcare Limited (Zydus)
- 9.3.11. ANI Pharmaceuticals, Inc.
- 9.3.12. Cipla Ltd.
- 9.3.13. Neurogastrx, Inc.

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes